SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, long-acting glucocorticoids (GCs) and/or multiple daily dose short-acting GCs are historically suggested to disease management. However, these treatment strategies are generally associated with GC overexposure, w...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Endocr Soc
Главные авторы: Simeoli, Chiara, Ferrigno, Rosario, Angellotti, Domenico, Iacuaniello, Davide, Pivonello, Claudia, Negri, Mariarosaria, Di Gennaro, Gilda, De Martino, Maria Cristina, Colao, Annamaria, Pivonello, Rosario
Формат: Artigo
Язык:Inglês
Опубликовано: Endocrine Society 2019
Предметы:
Adrenal
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552856/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-358
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы